PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35368048-4	2022	We have previously screened the Connectivity Map database to identify mebendazole as an anti-AML therapeutic targeting c-MYB.	Mebendazole	70-81	MYB proto-oncogene, transcription factor	Homo sapiens	119-124	
29089643-4	2018	Here, we have used a c-MYB gene expression signature from MLL-rearranged AML to probe the Connectivity Map database and identified mebendazole as a c-MYB targeting drug.	Mebendazole	131-142	MYB proto-oncogene, transcription factor	Homo sapiens	21-26	
29089643-4	2018	Here, we have used a c-MYB gene expression signature from MLL-rearranged AML to probe the Connectivity Map database and identified mebendazole as a c-MYB targeting drug.	Mebendazole	131-142	MYB proto-oncogene, transcription factor	Homo sapiens	148-153	
29089643-5	2018	Mebendazole induces c-MYB degradation via the proteasome by interfering with the heat shock protein 70 (HSP70) chaperone system.	Mebendazole	0-11	MYB proto-oncogene, transcription factor	Homo sapiens	20-25	
29089643-8	2018	In the context of widespread human use of mebendazole, our data indicate that mebendazole-induced c-MYB degradation represents a safe and novel therapeutic approach for AML.	Mebendazole	42-53	MYB proto-oncogene, transcription factor	Homo sapiens	98-103	
29089643-8	2018	In the context of widespread human use of mebendazole, our data indicate that mebendazole-induced c-MYB degradation represents a safe and novel therapeutic approach for AML.	Mebendazole	78-89	MYB proto-oncogene, transcription factor	Homo sapiens	98-103